Key Takeaways
- • TPG and Blackstone are seeking more than $4 billion in proceeds from the sale of a Hologic unit, representing a significant secondary market transaction from one of 2025's largest leveraged buyouts.
- • The divestiture is part of a broader deleveraging strategy for the private equity sponsors, allowing them to repay investor capital and reduce debt taken on during the original acquisition.
- • This sale signals PE sponsors' focus on capital efficiency and returning cash to limited partners in a competitive fundraising environment.
- • The transaction underscores the strategic value of Hologic's divisional assets and the continued appetite for healthcare-focused acquisitions in the market.
Summary
TPG and Blackstone are pursuing the sale of a Hologic business unit with a target valuation exceeding $4 billion, according to reports from the Financial Times. The move represents a key capital allocation decision for the two private equity sponsors and reflects their intent to unlock cash from one of last year's major leveraged buyouts.
The transaction serves a dual purpose for the PE firms: generating proceeds to repay investor distributions and reducing the overall debt burden carried on the acquisition. In competitive fundraising cycles, demonstrating strong capital returns and efficient portfolio management is critical for attracting institutional capital to new funds. By monetizing this asset relatively quickly after the initial investment, TPG and Blackstone are executing a classic PE playbook—acquiring large platforms, optimizing operations, and strategically exiting non-core or underweighting divisions to improve the overall risk-adjusted returns of the portfolio.
The $4 billion-plus valuation target reflects robust market demand for healthcare assets, particularly in the diagnostics and medical device sector. The ability to command such valuations in a secondary sale indicates the underlying business unit maintains strong operational metrics and market positioning, which could attract strategic buyers or financial sponsors seeking healthcare exposure.
This divestiture is consistent with broader PE activity in 2026, where sponsors are balancing leverage reduction with timely capital returns. For institutional investors and limited partners monitoring portfolio performance, the transaction demonstrates active management and value creation mechanisms at work post-acquisition.
The transaction serves a dual purpose for the PE firms: generating proceeds to repay investor distributions and reducing the overall debt burden carried on the acquisition. In competitive fundraising cycles, demonstrating strong capital returns and efficient portfolio management is critical for attracting institutional capital to new funds. By monetizing this asset relatively quickly after the initial investment, TPG and Blackstone are executing a classic PE playbook—acquiring large platforms, optimizing operations, and strategically exiting non-core or underweighting divisions to improve the overall risk-adjusted returns of the portfolio.
The $4 billion-plus valuation target reflects robust market demand for healthcare assets, particularly in the diagnostics and medical device sector. The ability to command such valuations in a secondary sale indicates the underlying business unit maintains strong operational metrics and market positioning, which could attract strategic buyers or financial sponsors seeking healthcare exposure.
This divestiture is consistent with broader PE activity in 2026, where sponsors are balancing leverage reduction with timely capital returns. For institutional investors and limited partners monitoring portfolio performance, the transaction demonstrates active management and value creation mechanisms at work post-acquisition.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.